FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:2597-2598 June 26, 2003 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Richardson, P. G. PubMed Citation

This is an exciting time for cancer therapeutics. The identification of promising molecular targets has led to the development of many exciting new drugs for which an antitumor mechanism of action has been clearly delineated. Given the recent major advances in our understanding of the biology of cancer cells, one might surmise that an era of truly rational therapeutics has arrived. Nevertheless, we continue to find new therapeutic agents that target unforeseen molecular pathways.

The report by Richardson et al. in this issue of the Journal (pages 2609–2617) brings to the fore a relatively new and unexpected target, the 26S . . . [Full Text of this Article]

Source Information

From the Division of Hematology/Oncology and the Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill.

This article has been cited by other articles:

• Ding, W.-X., Ni, H.-M., Gao, W., Chen, X., Kang, J. H., Stolz, D. B., Liu, J., Yin, X.-M. (2009). Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy. Molecular Cancer Therapeutics 8: 2036-2045 [Abstract] [Full Text]  
• Mogensen, T. H. (2009). Pathogen Recognition and Inflammatory Signaling in Innate Immune Defenses. Clin. Microbiol. Rev. 22: 240-273 [Abstract] [Full Text]  
• Mendler, J. H., Kelly, J., Voci, S., Marquis, D., Rich, L., Rossi, R. M., Bernstein, S. H., Jordan, C. T., Liesveld, J., Fisher, R. I., Friedberg, J. W. (2008). Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma. Ann Oncol 19: 1759-1764 [Abstract] [Full Text]  
• Wong, D. J., Nuyten, D. S.A., Regev, A., Lin, M., Adler, A. S., Segal, E., van de Vijver, M. J., Chang, H. Y. (2008). Revealing Targeted Therapy for Human Cancer by Gene Module Maps. Cancer Res. 68: 369-378 [Abstract] [Full Text]  
• Katzel, J. A., Hari, P., Vesole, D. H. (2007). Multiple Myeloma: Charging Toward a Bright Future. CA Cancer J Clin 57: 301-318 [Abstract] [Full Text]  
• An, J., Rettig, M. B. (2007). Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib. Molecular Cancer Therapeutics 6: 61-69 [Abstract] [Full Text]  
• Vij, N., Fang, S., Zeitlin, P. L. (2006). Selective Inhibition of Endoplasmic Reticulum-associated Degradation Rescues {Delta}F508-Cystic Fibrosis Transmembrane Regulator and Suppresses Interleukin-8 Levels: THERAPEUTIC IMPLICATIONS. J. Biol. Chem. 281: 17369-17378 [Abstract] [Full Text]  
• Pui, C.-H., Evans, W. E. (2006). Treatment of Acute Lymphoblastic Leukemia. NEJM 354: 166-178 [Full Text]  
• Hachem, A., Gartenhaus, R. B. (2005). Oncogenes as molecular targets in lymphoma. Blood 106: 1911-1923 [Full Text]  
• Arora, S., Yang, J.-M., Hait, W. N. (2005). Identification of the Ubiquitin-Proteasome Pathway in the Regulation of the Stability of Eukaryotic Elongation Factor-2 Kinase. Cancer Res. 65: 3806-3810 [Abstract] [Full Text]  
• Lun, M., Zhang, P. L., Siegelmann-Danieli, N., Blasick, T. M., Brown, R. E. (2005). Intracellular Inhibitory Effects of Velcade Correlate with Morphoproteomic Expression of Phosphorylated-Nuclear Factor-{kappa}B and p53 in Breast Cancer Cell Lines. Annals of Clinical & Laboratory Science 35: 15-24 [Abstract] [Full Text]  
• Mabuchi, S., Ohmichi, M., Nishio, Y., Hayasaka, T., Kimura, A., Ohta, T., Kawagoe, J., Takahashi, K., Yada-Hashimoto, N., Seino-Noda, H., Sakata, M., Motoyama, T., Kurachi, H., Testa, J. R., Tasaka, K., Murata, Y. (2004). Inhibition of Inhibitor of Nuclear Factor-{kappa}B Phosphorylation Increases the Efficacy of Paclitaxel in in Vitro and in Vivo Ovarian Cancer Models. Clin. Cancer Res. 10: 7645-7654 [Abstract] [Full Text]  
• Xia, X., Roundtree, M., Merikhi, A., Lu, X., Shentu, S., LeSage, G. (2004). Degradation of the Apical Sodium-dependent Bile Acid Transporter by the Ubiquitin-Proteasome Pathway in Cholangiocytes. J. Biol. Chem. 279: 44931-44937 [Abstract] [Full Text]  
• An, J., Sun, Y., Fisher, M., Rettig, M. B. (2004). Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-{kappa}B dependent. Molecular Cancer Therapeutics 3: 727-736 [Abstract] [Full Text]  
• Mabuchi, S., Ohmichi, M., Nishio, Y., Hayasaka, T., Kimura, A., Ohta, T., Saito, M., Kawagoe, J., Takahashi, K., Yada-Hashimoto, N., Sakata, M., Motoyama, T., Kurachi, H., Tasaka, K., Murata, Y. (2004). Inhibition of NF{kappa}B Increases the Efficacy of Cisplatin in in Vitro and in Vivo Ovarian Cancer Models. J. Biol. Chem. 279: 23477-23485 [Abstract] [Full Text]  
• Gao, W., Lam, W., Zhong, S., Kaczmarek, C., Baker, D. C., Cheng, Y.-C. (2004). Novel Mode of Action of Tylophorine Analogs as Antitumor Compounds. Cancer Res. 64: 678-688 [Abstract] [Full Text]